Emecalm DSR
Domperidone (30mg) + Pantoprazole (40mg) DSR

About this product
Targets Both Acid and Motility. DSR Formulation for Convenience. Dual-Mechanism Symptom Control. One Capsule, Better Compliance.

Overview
Emecalm DSR addresses key gaps in current approaches to GERD and dyspepsia with a motility component. By combining delayed-release enteric-coated pantoprazole with sustained-release domperidone in one once-daily DSR capsule, Emecalm DSR delivers dual-mechanism symptom control that addresses both the acid-secretion and gastric-motility components together, with domperidone's peripherally-selective action limiting central nervous system side effects and the single-capsule format supporting better patient adherence.
Indications
Related Products

UrsotOS 300
Ursodeoxycholic Acid (300mg)
Trusted long-term disease-modifying therapy for primary biliary cholangitis and chronic cholestatic liver disease.

EsomatOS 40
Esomeprazole (40mg)
Acid suppression for patients unable to take oral therapy, indicated in erosive GERD and prevention of rebleeding after endoscopic treatment of gastric or duodenal ulcers.
Partner With Schemic Concepts
Engineer better health outcomes with precision-driven pharmaceuticals
Healthcare is moving toward greater digital integration and evidence-based care. Schemic Concepts is built to move with it